Lymphoma

Patient Story: CAR-T Therapy Brings New Hope for Lymphoma Patients – A Case from a Chinese Hospital

**Patient Story: CAR-T Therapy Brings New Hope for Lymphoma Patients – A Case from a Chinese Hospital** In the field of cancer treatment, China has achieved groundbreaking success with CAR-T cell therapy, especially in treating relapsed or refractory lymphoma. Today, we share the story of one patient whose life was transformed through this revolutionary treatment Read More

November 12th,2024 patient story , CAR-T , Lymphoma

**Patient Story | Chinese CAR-T Therapy: An Inspiring Journey of Changing Fate for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)**

**Patient Story | Chinese CAR-T Therapy: An Inspiring Journey of Changing Fate for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)** #CAR-T #DLBCL #Lymphoma #CARTtherapy #RRDLBCL #Patientstory #CD19 In the field of cancer treatment, China has made remarkable strides in CAR-T cell therapy, especially in the fight against relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). Read More

November 7th,2024 CAR-T , Lymphoma , patient story

APBMT 2024丨Global Breakthrough of Chinese CAR-T Therapy: New Advances in the Treatment of Central Nervous System Lymphoma (CNSL)

### APBMT 2024丨Global Breakthrough of Chinese CAR-T Therapy: New Advances in the Treatment of Central Nervous System Lymphoma (CNSL) #CAR-T #CNSL #ASCT #APBMT2024 #CARTtherapy #CentralNervousSystemLymphoma #Lymphoma #RRCNSL #APBMT In the treatment of relapsed or refractory central nervous system lymphoma (R/R CNSL), Chinese CAR-T therapy is pioneering new directions worldwide. Conventional treatments for this disease have shown limited effectiveness, particularly when autologous stem Read More

November 7th,2024 CAR-T , Lymphoma

Beacon of Hope: China’s CAR-T Therapy Helps a TP53-Deficient Diffuse Large B-Cell Lymphoma(DLBCL) Patient Achieve Complete Remission

### Beacon of Hope: China’s CAR-T Therapy Helps a TP53-Deficient Diffuse Large B-Cell Lymphoma Patient Achieve Complete Remission #CAR-T #CancerTreatment #Lymphoma #DLBCL #PrecisionMedicine In an inspiring treatment case, a 38-year-old Chinese male patient with TP53-deficient Diffuse Large B-cell Lymphoma (DLBCL) achieved complete remission through Chinese CAR-T cell therapy. This remarkable outcome has sparked excitement about Read More

October 29th,2024 Lymphoma , CAR-T

Complete Remission In Just Two Months! China’s CAR-T Therapy Brings New Hope For Lymphoma (DLBCL) Patients!

Complete Remission In Just Two Months! China’s CAR-T Therapy Brings New Hope For Lymphoma (DLBCL) Patients! #Lymphoma #CAR_TCellTherapy #DLBCL#CancerHope #PatientStory Lymphoma has long been regarded as a “synonym for death,” with its high incidence and recurrence rates striking fear into many. However, with the rapid advancement of medical technology, a revolutionary new therapy is changing this Read More

October 23rd,2024 Lymphoma , CAR-T , patient story

China’s CAR-T Cell Therapy: Leading a New Revolution in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma (MCL)

  #CARTCellTherapy #MantleCellLymphoma #RelapsedMCL #RefractoryMCL #Hematology #MCL Mantle Cell Lymphoma (MCL), a rare and complex subtype of non-Hodgkin’s lymphoma, exhibits both aggressive and indolent characteristics. Since MCL patients are usually diagnosed at an advanced stage, often with poor prognostic factors, traditional treatments such as chemotherapy and immunotherapy have brought survival benefits to some patients. However, most Read More

October 23rd,2024 Lymphoma

Chinese Medical Team’s Fourth-Generation CAR-T Therapy: Revealing New Hope for B-Cell Lymphoma Treatment

Chinese Medical Team’s Fourth-Generation CAR-T Therapy: Revealing New Hope for B-Cell Lymphoma Treatment #CART #CellDiscovery #Lymphoma #BCellLymphoma #RRLBCL #IL7 #CCL19 In recent years, China has made significant progress in medical innovation, especially in the field of Chimeric Antigen Receptor T-cell (CAR-T) therapy, dramatically changing the landscape of treatment for malignant blood cancers. Recently, a team Read More

October 17th,2024 Lymphoma

What Types of Lymphoma Patients Are Suitable for CAR-T Treatment in China？

# What Types of Lymphoma Patients Are Suitable for CAR-T Treatment in China? #CART #Lymphoma #DLBCL #LBCL #MedicalTourism #FL #MCL In recent years, CAR-T cell therapy has sparked a revolution in cancer treatment worldwide, achieving remarkable results, especially in lymphoma care. As one of the global leaders in CAR-T therapy, China has attracted a large Read More

October 17th,2024 Lymphoma

China Leads the CAR-T Therapy Revolution, Reshaping the Treatment Landscape of Large B-Cell Lymphoma—2024 CSCO Annual Meeting

**China Leads the CAR-T Therapy Revolution, Reshaping the Treatment Landscape of Large B-Cell Lymphoma—2024 CSCO Annual Meeting** #CSCO #CSCO2024 #Lymphoma #CART #LBCL #RRLBCL #ChinaCAR-T At the 27th Annual Chinese Society of Clinical Oncology (CSCO) Conference, held in Xiamen, China, CAR-T therapy took center stage as a key focus for the treatment of large B-cell lymphoma Read More

October 14th,2024 Lymphoma

CAR-T Immune Cell Therapy for Lymphoma: A Comprehensive Guide

CAR-T cell therapy offers significant efficacy in treating lymphoma, bringing new hope to patients.

October 12th,2024 Lymphoma

Tecartus and Non Hodgkin’s Lymphoma

Tecartus represents a groundbreaking advancement in the treatment of relapsed or refractory mantle cell lymphoma, a subtype of non-Hodgkin’s lymphoma.

October 12th,2024 Lymphoma

Yescarta Treatment: A Comprehensive Overview

Yescarta, also known as axicabtagene ciloleucel, is a revolutionary immunotherapy treatment that has shown significant promise in the field of oncology, particularly for certain types of lymphomas.

October 10th,2024 Lymphoma